← Back to Home

Intranasal mRNA therapy ETH47 lowers rhinovirus load; benefits for asthma symptoms remain to be verified

A 50-person viral challenge trial showed that a single intranasal dose of ETH47 could suppress rhinovirus load, but respiratory symptoms, the study’s primary measure, have so far shown only a trend toward numerical improvement. A clinical evidence hurdle remains between strengthening local antiviral defenses and reducing asthma exacerbations.

By SURL BioNews

For people with asthma, respiratory viral infections can trigger a worsening of their condition. Could strengthening local defenses as a virus enters the airways lessen subsequent symptoms? On November 5, German biotechnology company Ethris announced preliminary results from a phase 2a trial of its intranasal mRNA therapy candidate ETH47: viral load in treated participants on day 2 after viral challenge was approximately one-fortieth that of the placebo group. Whether this reduction in viral load translates into clear clinical benefits, however, remains unresolved.

ETH47 carries mRNA encoding interferon lambda (IFNλ), with the aim of prompting local airway cells to produce this antiviral protein involved in innate immunity. Its development approach is to suppress viral replication by strengthening the host’s mucosal defenses. This trial provides a preliminary signal of antiviral activity in humans, but it does not establish that ETH47 can prevent infections in everyday life or reduce the risk of acute asthma exacerbations.

The randomized, double-blind, placebo-controlled study enrolled 50 adults with asthma. According to the company’s announcement, participants continued their existing inhaled maintenance therapy, received a single intranasal dose of ETH47 or placebo, and were exposed to rhinovirus A16 under controlled conditions the following day, with follow-up through day 42. The ISRCTN registry confirms the study design and final enrollment, recording that enrollment began in June 2025 and the trial was completed in September 2026.

The key to interpreting the results is that viral load was not the study’s primary endpoint. The company’s announcement stated that the primary endpoint was the lower respiratory tract symptom score; its current descriptions of symptoms, mild exacerbations, and rescue medication use all indicate trends toward numerical improvement compared with placebo. The announcement did not provide a complete analysis sufficient to determine whether the primary endpoint reached statistical significance. The difference in viral load on day 2 therefore cannot be interpreted directly as proof of efficacy in treating asthma.

In an exploratory analysis, the company also found that participants with higher IFNλ exposure showed stronger signals of antiviral activity and symptom improvement. This association could inform subsequent adjustments to dose and dosing frequency, but the exploratory subgroup findings still require validation in new studies and cannot replace the primary endpoint analysis for the overall study population.

On safety, Ethris stated that no severe or serious adverse events occurred in this single-dose study. However, short-term observation of 50 people remains insufficient to clarify rare risks or the safety of repeated dosing. There are also gaps in the publicly available evidence: the ISRCTN record shows that delayed disclosure of full trial details was approved by the UK Health Research Authority. The registry page currently provides neither study results nor a statistical analysis plan, making it difficult for outside observers to fully assess the company’s preliminary conclusions.

Ethris next plans to conduct multiple-dose studies in patients with asthma and chronic obstructive pulmonary disease, and to advance subsequent viral challenge studies and a phase 2b trial in a natural infection setting. For ETH47, the central question ahead is whether its local antiviral activity can consistently translate into fewer symptoms and a lower burden of exacerbations in larger studies that more closely reflect everyday infection settings.

References

  1. Ethris via GlobeNewswire
  2. Ethris GmbH
  3. ISRCTN registry